Back to homepage

Primary Care

Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin

Authors: Jeffrey Freeman

In this article the author discusses the implications for clinical practice of the results of a recent Phase III trial. He concludes that initial combination of linagliptin plus metformin which was found to be weight neutral, well tolerated and associated with a low frequency of hypoglycaemia, may have advantages for a large proportion of patients with type 2 diabetes, particularly those with a relatively high HbA1c at diagnosis.

More

Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes

Authors: Stanley S Schwartz

In this article the author argues that in type 2 diabetes, an approach that emphasizes diet and exercise and features a treatment regimen tailored to the needs of the individual to reach glycemic targets is warranted in most patients and provides microvascular and cardiovascular benefit, provided that hypoglycemia is avoided.

More

Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?

Authors: Eva Vivian, Chelsea Mannebach

In this article authors review recent studies and evaluate the benefits and risks of combination therapy with an angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB), or a direct renin inhibitor (DRI) to attenuate the progression of diabetic nephropathy.

More

Cardiovascular consequences of obesity: how will the UK cope?

Authors: Henry Purcell

It is estimated that by 2050, the majority of Britain’s population will be obese. In this article, Dr Henry Purcell discusses the cardiovascular consequences of obesity and what needs to be done to equip healthcare professionals with the tools and training to help prevent and treat weight-related diseases.

More

Vaccination against meningitis B: is it worth it?

Authors: Peter English

When a new vaccine is licensed having passed the tests for efficacy and safety, governments who have to pay for it to be used, as in the UK, will carry out a careful economic appraisal before making it generally available. In this challenging article, Dr Peter English discusses whether or not a new vaccine for meningitis that has just been licensed and that could save lives is actually worth it.

More